Company Future Sales Volume: TransCode (RNAZ)

TransCode Therapeutics specializes in developing DNA-based cancer therapies. The company's sales expectations demonstrate market potential, where the value of 0.00 indicates the current magnitude. The firm relies on high-precision RNA platforms, automates genetic analysis using robotics, and efficiently delegates clinical trials to external contractors to reduce internal costs.

TransCode Therapeutics - RNAZ Company Projected Revenue Volume (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for TransCode (RNAZ)

- stock quotes and analyst forecast:

Stock Price TransCode Therapeutics|RNAZ - Average Forecast Price

- company stock exchange capitalization indicators:

Market Valuation TransCode Therapeutics Inc.|RNAZ - Value Adjusted for Debt and Cash

- issuer book value statistics:

Accounting Value per Share TransCode Therapeutics|RNAZ - Total Net Assets|Market Capitalization to Book Value Ratio transcodetherapeutics.com|RNAZ - Aggregate Asset Value

- debt burden and liquidity indicators:

Total Debt to Capital TransCode Therapeutics|RNAZ - Long-Term Liabilities to Capital|Short-Term Debt to Equity TransCode Therapeutics|RNAZ - Aggregate Debt Obligations|Debts to Book Capitalization TransCode Therapeutics Inc.|RNAZ - Company Long-Term Debts|Company Short-Term Debt TransCode Therapeutics|Quick Ratio transcodetherapeutics.com

- financial results and valuation multiples details:

RNAZ - Company Net Income|Future Profit TransCode Therapeutics|RNAZ - P/E Multiple|Projected Price to Earnings TransCode Therapeutics|RNAZ - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple TransCode Therapeutics Inc.|RNAZ - Operating income before deduction of amortization|Net earnings per share (EPS TTM) TransCode Therapeutics|RNAZ - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months transcodetherapeutics.com|RNAZ - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year TransCode Therapeutics

- company sales and revenue statistics:

RNAZ - Company Sales Revenue|Company Projected Revenue TransCode Therapeutics|RNAZ - Market Cap to Revenue Ratio|Forward P/S Multiple TransCode Therapeutics Inc.

Fundamental valuation:TransCode Therapeutics, Inc.

The calculation formula for this indicator is based on the correlation between operating cash flows and projected revenues. This metric determines the market value of the asset by assessing its resilience to volatility and the risk of deep drawdowns. For TransCode Therapeutics (RNAZ), such calculations are critical due to sanction barriers regarding the exchange of genetic data. Geopolitical restrictions on reagents directly compress the potential of future contracts. By analyzing the trend of the firm's sales performance, an investor can discern the business's actual margin of safety.

Analysis of competing companies